ZURICH (Reuters) Aug 27 - Swiss drugmaker Novartis AG said on Monday its Rasilez (aliskiren) treatment for high blood pressure had been approved for use in the European Union.
Aug 17th 诺华公司对外宣布，抗高血压药物Rasilez 已经获欧盟批准
Rasilez, which is known as Tekturna in the United States, was co-developed by Swiss biotech company Speedel, and has already been approved in the United States and Switzerland.
Rasilez，美国称Tekturna，此前在美国和瑞士已经获批。诺华与瑞士生物公司Speedel合作开发的新产品
The EU approval had been expected after Rasilez was recommended by a European panel of experts.
此前经过欧盟专家组成员推荐，该产品以有望获EU批准
The European Commission approved the drug for use alone or in combination with other high blood pressure treatments. The approval applies to all 27 EU member states plus Iceland and Norway.
欧盟委员会批准该产品除可在EU27各成员国外，还可在冰岛和挪威两国使用。临床应用方式：单独应用或与其它抗高血压药物联用。
Rasilez, a once-daily pill, is the first of a new class of renin inhibitors, which could offer additional benefits compared with older medications
日给药量及次数，1粒/天，第一种全新肾素抑制剂，于其他类似药物相比有几种特别的临床应用优势
Aug 17th 诺华公司对外宣布，抗高血压药物Rasilez 已经获欧盟批准
Rasilez, which is known as Tekturna in the United States, was co-developed by Swiss biotech company Speedel, and has already been approved in the United States and Switzerland.
Rasilez，美国称Tekturna，此前在美国和瑞士已经获批。诺华与瑞士生物公司Speedel合作开发的新产品
The EU approval had been expected after Rasilez was recommended by a European panel of experts.
此前经过欧盟专家组成员推荐，该产品以有望获EU批准
The European Commission approved the drug for use alone or in combination with other high blood pressure treatments. The approval applies to all 27 EU member states plus Iceland and Norway.
欧盟委员会批准该产品除可在EU27各成员国外，还可在冰岛和挪威两国使用。临床应用方式：单独应用或与其它抗高血压药物联用。
Rasilez, a once-daily pill, is the first of a new class of renin inhibitors, which could offer additional benefits compared with older medications
日给药量及次数，1粒/天，第一种全新肾素抑制剂，于其他类似药物相比有几种特别的临床应用优势